Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2008

Conditions
Cytomegalovirus Infection
Interventions
DRUG

Single arm (ganciclovir and valganciclovir)

Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)

Trial Locations (1)

08907

Hospital Universitari Bellvitge- Transplant Departments (Liver, Heart and Kidney), L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Salvador Gil-Vernet

OTHER

NCT00730769 - Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients | Biotech Hunter | Biotech Hunter